The Life Sciences team advised Ionpath, Inc. on its strategic investment by Thermo Fisher Scientific.
Ionpath, Inc., based in Menlo Park, California, is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. With its MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.
Thermo Fisher Scientific (NYSE: TMO), headquartered in Waltham, Massachusetts, is a global provider of medical equipment, analytical instruments, reagents and consumables, software and services to tackle complex analytical challenges in research, diagnostics and clinical laboratories, with annual revenue of approximately $40 billion.
The Goodwin team was led by Richard Hoffman, Shoaib Ghias and Steve Argentieri. Goodwin has represented Ionpath since its early stage, including in its Series A and Series B preferred stock financings.
For more details, read the press release and article in GenomeWeb.